Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Presence of certain proteins in HDL can lead to cardiovascular risk

Presence of certain proteins in HDL can lead to cardiovascular risk

A current study by the MedUni Vienna has shown that changes to the "good cholesterol" HDL (High-Density Lipoprotein) can be associated with cardiovascular diseases: by developing a new laboratory test, scientists at the Institute of Medical Genetics and the Department of Nephrology & Dialysis (University Department of Internal Medicine III) at the MedUni Vienna have demonstrated for the first time that the presence of certain proteins in the HDL can lead to an increased risk of cardiovascular disease and mortality. [More]
Preconception care can significantly lower adverse birth outcomes in diabetic women

Preconception care can significantly lower adverse birth outcomes in diabetic women

Pregnant women with diabetes are at an increased risk for many adverse birth outcomes. Preconception care (PCC) can significantly lower these risks by helping pregnant mothers with diabetes control their glucose levels, resulting in healthier babies and less money spent on complicated deliveries and lifelong medical complications. [More]
Five USF faculty members named AAAS Fellow

Five USF faculty members named AAAS Fellow

Five faculty members from the University of South Florida in Tampa have been named Fellows of the American Association for the Advancement of Science. Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. [More]
No added benefit proven for empagliflozin in type 2 diabetes

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. [More]
Scientists unravel molecular mechanisms that drive ferroptosis signaling

Scientists unravel molecular mechanisms that drive ferroptosis signaling

Ferroptosis is a recently recognized form of regulated necrosis. Up until now, this form of cell death has only been thought to be a possible therapeutic approach to treat tumour cells. Yet, ferroptosis also occurs in non-transformed tissues as demonstrated by this study, thus implicating this cell death pathway in the development of a wide range of pathological conditions. More specifically, the deletion of the ferroptosis-regulating enzyme Gpx4 in a pre-clinical model results in high ferroptosis rates in kidney tubular epithelial cells causing acute renal failure. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]
Lifestyle of young people could pose risk for developing diabetes mellitus

Lifestyle of young people could pose risk for developing diabetes mellitus

Research performed by the University of Veracruz, in the east coast of Mexico, called Lifestyles Nutrition Students and Risk of Type II Diabetes, showed that the lifestyle of young people between 17 and 24 years of age, like lack of physical activity, mild psychological stress, and the omission of breakfast could pose a risk for developing diseases such as diabetes mellitus. [More]

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium levels). The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014. [More]
Study examines overall survival of patients with chronic HCV infection, cirrhosis

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA. [More]
Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. [More]
Depression, anxiety after MI more common in women than men

Depression, anxiety after MI more common in women than men

Women are more likely to develop anxiety and depression after a heart attack (myocardial infarction; MI) than men, according to research presented at Acute Cardiovascular Care 2014 by Professor Pranas Serpytis from Lithuania. [More]
Mexican students create zero calorie sweetener for people with diabetes, hypertension, obesity

Mexican students create zero calorie sweetener for people with diabetes, hypertension, obesity

Since Elsa Martinez was diagnosed with type II diabetes she made sure to be informed about those food products that wouldn't aggravate her health. [More]
Consultant Live unveils new online sleep disorders educational program for doctors, nurses

Consultant Live unveils new online sleep disorders educational program for doctors, nurses

UBM Medica US announces that Consultant Live a leading online community for primary care clinicians, has unveiled a new online sleep disorders educational program to help doctors and nurses help their patients get a good night's rest. [More]
Magnesium essential to the activity of vitamin D

Magnesium essential to the activity of vitamin D

Extensive research has shown that vitamin D deficiencies play a major role in the development of dozens of diseases, including breast, prostate and colon cancer, as well as diabetes, heart disease, arthritis, osteoporosis, psoriasis and mental illness. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Chronic consumption of melatonine helps combat obesity, diabetes

Chronic consumption of melatonine helps combat obesity, diabetes

Scientists at the University of Granada, in collaboration with La Paz University Hospital in Madrid and the University of Texas, San Antonio in the US have demonstrated through several experiments conducted on Zucker obese rats that chronic consumption of melatonine helps combat obesity and diabetes mellitus type two. [More]
Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). [More]
EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its CE Mark for the Maestro Rechargeable (RC) System for obesity was expanded to include the management of Type 2 diabetes mellitus through improved glycemic control. [More]
Storage symptoms more severe in men with comorbid diabetes

Storage symptoms more severe in men with comorbid diabetes

A study of men with lower urinary tract symptoms and benign prostatic hyperplasia suggests that the presence of comorbid diabetes is associated with more severe urological symptoms. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]